Hyperkalemia is referred to as increased levels
of potassium in blood which results in cardiac arrest and death. Potassium
levels above 5.1 mEq/l are considered as the hyperkalemia condition. The main
causes of hyperkalemia are potassium sifting out of cells into the blood circulation,
adrenal gland diseases, kidney dysfunction, uncontrolled diabetes, breakdown of
muscle tissue and red blood cells.
Access
Detailed Report Summary: https://www.pharmaproff.com/report/hyperkalemia-therapeutics-pipeline-analysis
Hyperkalemia
causes abnormal heart rhythms and also interferes in the functioning of the
skeletal muscles. The common symptoms associated with the hyperkalemia are
fatigue, nausea, muscle weakness and tingling sensations.
Request
to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1155
The standard
treatment strategies for hyperkalemia are intravenous administration of glucose
and insulin, a diet low in potassium, medications that stimulate beta-2 adrenergic
receptors, sodium bicarbonate administration and discontinue medications that
increase blood potassium levels. Ardelyx Inc. is developing RDX013 which acts
as a potassium secretagogue for the treatment of hyperkalemia. Relypsa Inc. is
another key player involved in the development of drugs for the treatment of
hyperkalemia.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment